These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15201106)

  • 21. Integrative harm reduction psychotherapy: a case of substance use, multiple trauma, and suicidality.
    Tatarsky A; Kellogg S
    J Clin Psychol; 2010 Feb; 66(2):123-35. PubMed ID: 20088005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contested space in the pharmacy: public attitudes to pharmacy harm reduction services in the West of Scotland.
    Gidman W; Coomber R
    Res Social Adm Pharm; 2014; 10(3):576-87. PubMed ID: 24021859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. State of the art in harm reduction psychotherapy: an emerging treatment for substance misuse.
    Tatarsky A; Marlatt GA
    J Clin Psychol; 2010 Feb; 66(2):117-22. PubMed ID: 20049922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bridging the gap in San Francisco: the process of integrating harm reduction and traditional substance abuse services.
    Gleghorn A; Rosenbaum M; Garcia BA
    J Psychoactive Drugs; 2001; 33(1):1-7. PubMed ID: 11332995
    [No Abstract]   [Full Text] [Related]  

  • 25. Update on harm-reduction policy and intervention research.
    Marlatt GA; Witkiewitz K
    Annu Rev Clin Psychol; 2010; 6():591-606. PubMed ID: 20192791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Casting light on harm reduction: introducing two instruments for analysing contradictions between harm reduction and 'non-harm reduction'.
    Jourdan M
    Int J Drug Policy; 2009 Nov; 20(6):514-20. PubMed ID: 19349155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addressing adolescent substance use with a public health prevention framework: the case for harm reduction.
    Winer JM; Yule AM; Hadland SE; Bagley SM
    Ann Med; 2022 Dec; 54(1):2123-2136. PubMed ID: 35900132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards the integration of treatment systems for substance abusers: report on the second International Symposium on Substance Abuse Treatment and Special Target Groups.
    Broekaert E; Vanderplasschen W
    J Psychoactive Drugs; 2003; 35(2):237-45. PubMed ID: 12924746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Harm reduction coming of age: A summary of the '18th International Conference on the Reduction of Drug Related Harm'-Warsaw, Poland: 13-17 May 2007.
    Moskalewicz J; Barrett D; Bujalski M; Dabrowska K; Klingemann H; Klingemann J; Malczewski A; Struzik M
    Int J Drug Policy; 2007 Dec; 18(6):503-8. PubMed ID: 18061432
    [No Abstract]   [Full Text] [Related]  

  • 30. Training the next generation of providers in addiction medicine.
    Rasyidi E; Wilkins JN; Danovitch I
    Psychiatr Clin North Am; 2012 Jun; 35(2):461-80. PubMed ID: 22640766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incongruence between trauma center social workers' beliefs about substance use interventions and intentions to intervene.
    Davis D; Hawk M
    Soc Work Health Care; 2015; 54(4):320-44. PubMed ID: 25905765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The implementation of a harm minimisation model for the identification and treatment of over-the-counter drug misuse and abuse in community pharmacies in Northern Ireland.
    Wazaify M; Hughes CM; McElnay JC
    Patient Educ Couns; 2006 Dec; 64(1-3):136-41. PubMed ID: 16431072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role and development of the Asian Harm Reduction Network.
    Tanguay PF; Smits T
    Int J Drug Policy; 2007 Mar; 18(2):148-51. PubMed ID: 17689359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How the harm reduction movement contrasts itself against punitive prohibition.
    Tammi T; Hurme T
    Int J Drug Policy; 2007 Mar; 18(2):84-7. PubMed ID: 17689349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study.
    Petry NM; Peirce JM; Stitzer ML; Blaine J; Roll JM; Cohen A; Obert J; Killeen T; Saladin ME; Cowell M; Kirby KC; Sterling R; Royer-Malvestuto C; Hamilton J; Booth RE; Macdonald M; Liebert M; Rader L; Burns R; DiMaria J; Copersino M; Stabile PQ; Kolodner K; Li R
    Arch Gen Psychiatry; 2005 Oct; 62(10):1148-56. PubMed ID: 16203960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substance use management: a harm reduction-principled approach to assisting the relief of drug-related problems.
    Bigg D
    J Psychoactive Drugs; 2001; 33(1):33-8. PubMed ID: 11332999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harm reduction therapy with families and friends of people with drug problems.
    Denning P
    J Clin Psychol; 2010 Feb; 66(2):164-74. PubMed ID: 20049921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managed care and the quality of substance abuse treatment.
    Shepard DS; Daley M; Ritter GA; Hodgkin D; Beinecke RH
    J Ment Health Policy Econ; 2002 Dec; 5(4):163-74. PubMed ID: 14578550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The issue of harm reduction in Polish legislation concerning drug addiction. A comparative study].
    Sobeyko J
    Ann Acad Med Stetin; 2008; 54(2):119-31. PubMed ID: 19374242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Public Health and the origins of the Mersey Model of Harm Reduction.
    Ashton JR; Seymour H
    Int J Drug Policy; 2010 Mar; 21(2):94-6. PubMed ID: 20163946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.